Characterization of the MADH2/Smad2 gene, a human Mad homolog responsible for the transforming growth factor-β and activin signal transduction pathway

Genomics

Volumn 48, Issue 1, 1998, Pages 1-11

  Takenoshita, Seiichi ^a   Mogi, Akira ^a   Nagashima, Makoto ^b   Yang, Ke ^c   Yagi, Ken ^a,d   Hanyu, Aki ^d   Nagamachi, Yukio ^a   Miyazono, Kohei ^d   Hagiwara, Koichi ^b  

^a GUNMA UNIVERSITY   (Japan)

^b NATIONAL CANCER INSTITUTE   (United States)

^c PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^d JAPAN SOCIETY FOR THE PROMOTION OF SCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN; COMPLEMENTARY DNA; CYTOKINE; MESSENGER RNA; PROTEIN SERINE THREONINE KINASE; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; CANCER CELL; CARCINOGENESIS; CELL TRANSFORMATION; COLON CANCER; GENE EXPRESSION REGULATION; GENE MUTATION; GENOME; HEART; HUMAN; HUMAN CELL; LUNG CANCER; NUCLEOTIDE SEQUENCE; PLACENTA; PRIORITY JOURNAL; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; SKELETAL MUSCLE;

EID: 0031889595     PISSN: 08887543     EISSN: None     Source Type: Journal    
DOI: 10.1006/geno.1997.5149     Document Type: Article

References (55)

1. Baker J. C., Harland R. M. A novel mesoderm inducer, Madr2, functions in the activin signal transduction pathway. Genes Dev. 10:1996;1880-1889.
2. Bird A. P. CpG-rich islands and the function of DNA methylation. Nature. 321:1986;209-213.
3. Bradford M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:1976;248-254.
4. Breathnach R., Benoist C., O'Hare K., Gannon F., Chambon P. Ovalbumin gene: Evidence for a leader sequence in mRNA and DNA sequences at the exon-intron boundaries. Proc. Natl. Acad. Sci. USA. 75:1978;4853-4857.
5. Briggs M. R., Kadonaga J. T., Bell S. P., Tjian R. Purification and biochemical characterization of the promoter-specific transcription factor, Spl. Science. 234:1986;47-52.
6. Chen X., Rubock M. J., Whitman M. A transcriptional partner for MAD proteins in TGF-β signalling. Nature. 383:1996;691-696.
7. Chen Y., Lebrun J.-J., Vale W. Regulation of transforming growth factor β- and activin-induced transcription by mammalian Mad proteins. Proc. Natl. Acad. Sci. USA. 93:1996;12992-12997.
8. Cheng S., Chang S. C., Gravitt P., Respess R. Long PCR. Nature. 369:1994;684-685.
9. Costello J. F., Berger M. S., Huang H. S., Cavenee W. K. Silencing of p16/CDKN2 expression in human gliomas by methylation and chromatin condensation. Cancer Res. 56:1996;2405-2410.
10. Derynck R., Zhang Y. Intracellular signalling: The Mad way to do it. Curr. Biol. 6:1996;1226-1229.
11. Derynck R., Gelbart W. M., Harland R. M., Heldin C.-H., Kern S., Massagué J., Melton D. A., Mlodzik M., Padgett R. W., Roberts A. B., Smith J., Thomsen G. H., Vogelstein B., Wang X.-F. Nomenclature: Vertebrate mediators of TGFβ family signals. Cell. 87:1996.
12. Eppert K., Scherer S. W., Ozcelik H., Pirone R., Hoodless P., Kim H., Tsui L.-C., Bapat B., Gallinger S., Andrulis I. L., Thomsen G. H., Wrana J. L., Attisano L. MADR2 maps to 18q21 and encodes a TGFβ-regulated MAD-related protein that is functionally mutated in colorectal carcinoma. Cell. 86:1996;543-552.
13. Gardiner-Garden M., Frommer M. CpG islands in vertebrate genomes. J. Mol. Biol. 196:1987;261-282.
14. Graff J. M., Bansal A., Melton D. A. Xenopus Mad proteins transduce distinct subsets of signals for the TGFβ superfamily. Cell. 85:1996;479-487.
15. Hagiwara K., Harris C. C. 'Long distance sequencer' method: A novel strategy for large DNA sequencing projects. Nucleic Acids Res. 24:1996;2460-2461.
16. Hahn S. A., Schutte M., Hoque A. T., Moskaluk C. A., da Costa L. T., Rozenblum E., Weinstein C. L., Fischer A., Yeo C. J., Hruban R. H., Kern S. E. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science. 271:1996;350-353.
17. Hanks S. K., Quinn A. M., Hunter T. The protein kinase family: Conserved features and deduced phylogeny of the catalytic domains. Science. 241:1988;42-52.
18. Harris C. C. Structure and function of the p53 tumor suppressor gene: Clues for rational cancer therapeutic strategies. J. Natl. Cancer Inst. 88:1996;1442-1455.
19. Hayashi H., Abdollah S., Qiu Y., Cai J., Xu Y. Y., Grinnell B. W., Richardson M. A., Topper J. N., Gimbrone M. A. Jr., Wrana J. L., Falb D. The MAD-related protein Smad7 associates with the TGFβ receptor and functions as an antagonist of TGFβ signaling. Cell. 89:1997;1165-1173.
20. Heldin C.-H., Miyazono K., ten Dijke P. TGF-β signalling from cell membrane to nucleus via Smad proteins. Nature. 390:1997;465-471.
21. Herman J. G., Merlo A., Mao L., Lapidus R. G., Issa J. P., Davidson N. E., Sidransky D., Baylin S. B. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res. 55:1995;4525-4530.
22. Hoodless P. A., Haerry T., Abdollah S., Stapleton M., O'Connor M. B., Attisano L., Wrana J. L. MADR1, a MAD-related protein that functions in BMP2 signaling pathways. Cell. 85:1996;489-500.
23. Imamura T., Takase M., Nishihara A., Oeda E., Hanai J.-i., Kawabata M., Miyazono K. Smad6 inhibits signalling by the TGF-β superfamily. Nature. 389:1997;622-626.
24. Kingsley D. M. The TGF-β superfamily: New members, new receptors, and new genetic tests of function in different organisms. Genes Dev. 8:1994;133-146.
25. Lagna G., Hata A., Hemmati-Brivanlou A., Massagué J. Partnership between DPC4 and SMAD proteins in TGF-β signalling pathways. Nature. 383:1996;832-836.
26. Lechleider R. J., de Caestecker M. P., Dehejia A., Polymeropoulos M. H., Roberts A. B. Serine phosphorylation, chromosomal localization, and transforming growth factor-β signal transduction by human bsp-l. J. Biol. Chem. 271:1996;17617-17620.
27. Liu F., Hata A., Baker J. C., Doody J., Carcamo J., Harland R. M., Massagué J. A human Mad protein acting as a BMP-regulated transcriptional activator. Nature. 381:1996;620-623.
28. Lu S. L., Akiyama Y., Nagasaki H., Saitoh K., Yuasa Y. Mutations of the transforming growth factor-β type II receptor gene and genomic instability in hereditary nonpolyposis colorectal cancer. Biochem. Biophys. Res. Commun. 216:1995;452-457.
29. Macias-Silva M., Abdollah S., Hoodless P. A., Pirone R., Attisano L., Wrana J. L. MADR2 is a substrate of the TGFβ receptor and its phosphorylation is required for nuclear accumulation and signaling. Cell. 87:1996;1215-1224.
30. Markowitz S., Wang J., Myeroff L., Parsons R., Sun L. Z., Lutterbaugh J., Fan R. S., Zborowska E., Kinzler K. W., Vogelstein B., Brattain M., Willson J. K. V. Inactivation of the type II TGF-β receptor in colon cancer cells with microsatellite instability. Science. 268:1995;1336-1338.
31. Massagué J. TGFβ signaling: Receptors, transducers, and Mad proteins. Cell. 85:1996;947-950.
32. Nagatake M., Takagi Y., Osada H., Uchida K., Mitsudomi T., Saji S., Shimokata K., Takahashi T., Takahashi T. Somatic in vivo alterations of the DPC4 gene at 18q21 in human lung cancers. Cancer Res. 56:1996;2718-2720.
33. Nakao A., Afrakhte M., Morén A., Nakayama T., Christian J. L., Heuchel R., Itoh S., Kawabata M., Heldin N.-E., Heldin C.-H., ten Dijke P. Identification of Smad7, a TGF-β-inducible antagonist of TGF-β signalling. Nature. 389:1997a;631-635.
34. Nakao A., Röijer E., Imamura T., Souchelnytskyi S., Stenman G., Heldin C.-H., ten Dijke P. Identification of Smad2, a human MAD-related protein in the TGF-β signaling pathway. J. Biol. Chem. 272:1997b;2896-2900.
35. INK4. Proc. Natl. Acad. Sci. USA. 91:1994;11045-11049.
36. Parsons R., Myeroff L. L., Liu B., Willson J. K., Markowitz S. D., Kinzler K. W., Vogelstein B. Microsatellite instability and mutations of the transforming growth factor β type II receptor gene in colorectal cancer. Cancer Res. 55:1995;5548-5550.
37. Pierce D. F. Jr., Gorska A. E., Chytil A., Meise K. S., Page D. L., Coffey R. J. Jr., Moses H. L. Mammary tumor suppression by transforming growth factor β1 transgene expression. Proc. Natl. Acad. Sci. USA. 92:1995;4254-4258.
38. Reed A. L., Califano J., Cairns P., Westra W. H., Jones R. M., Koch W., Ahrendt S., Eby Y., Sewell D., Nawroz H., Bartek J., Sidransky D. High frequency of p16 (CDKN2/MTS-1/INK4A. Cancer Res. 56:1996;3630-3633.
39. Riggins G. J., Thiagalingam S., Rozenblum E., Weinstein C. L., Kern S. E., Hamilton S. R., Willson J. K. V., Markowitz S. D., Kinzler K. W., Vogelstein B. Mad-related genes in the human. Nature Genet. 13:1996;347-349.
40. Sambrook J., Fritsch E. F., Maniatis T. Molecular Cloning: A Laboratory Manual. 1989;Cold Spring Harbor Laboratory Press, Cold Spring Harbor.
41. Savage C., Das P., Finelli A. L., Townsend S. R., Sun C.-Y., Baird S. E., Padgett R. W. Caenorhabditis elegans. Proc. Natl. Acad. Sci. USA. 93:1996;790-794.
42. Schutte M., Hruban R. H., Hedrick L., Cho K. R., Nadasdy G. M., Weinstein C. L., Bova G. S., Isaacs W. B., Cairns P., Nawroz H., Sidransky D., Casero R. A. Jr., Meltzer P. S., Hahn S. A., Kern S. E. DPC4 gene in various tumor types. Cancer Res. 56:1996;2527-2530.
43. Sekelsky J. J., Newfeld S. J., Raftery L. A., Chartoff E. H., Gelbart W. M. Genetic characterization and cloning of mothers against dpp, a gene required for decapentaplegic function in Drosophila melanogaster. Genetics. 139:1995;1347-1358.
44. Sheets M. D., Ogg S. C., Wickens M. P. Point mutations in AAUAAA and the poly(A) addition site: Effects on the accuracy and efficiency of cleavage and polyadenylation in vitro. Nucleic Acids Res. 18:1990;5799-5805.
45. Sun L., Wu G., Willson J. K., Zborowska E., Yang J., Raijkarunanayake I., Wang J., Gentry L. E., Wang X.-F., Brattain M. G. Expression of transforming growth factor β type II receptor leads to reduced malignancy in human breast cancer MCF-7 cells. J. Biol. Chem. 269:1994;26449-26455.
46. Takenoshita S., Hagiwara K., Nagashima M., Gemma A., Bennett W. P., Harris C. C. The genomic structure of the gene encoding the human transforming growth factor β type II receptor (TGF-β RII). Genomics. 36:1996;341-344.
47. Takenoshita S., Tani M., Nagashima M., Hagiwara K., Bennett W. P., Yokota J., Harris C. C. Mutation analysis of coding sequences of the entire transforming growth factor beta type II receptor gene in sporadic human colon cancer using genomic DNA and intron primers. Oncogene. 14:1997;1255-1258.
48. ten Dijke P., Miyazono K., Heldin C.-H. Signaling via hetero-oligomeric complexes of type I and type II serine/threonine kinase receptors. Curr. Opin. Cell Biol. 8:1996;139-145.
49. Thiagalingam S., Lengauer C., Leach F. S., Schutte M., Hahn S. A., Overhauser J., Willson J. K. V., Markowitz S., Hamilton S. R., Kern S. E., Kinzler K. W., Vogelstein B. Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers. Nature Genet. 13:1996;343-346.
50. Uchida K., Nagatake M., Osada H., Yatabe Y., Kondo M., Mitsudomi T., Masuda A., Takahashi T., Takahashi T. Somatic in vivo alterations of the JV18-1 gene at 18q21 in human lung cancers. Cancer Res. 56:1996;5583-5585.
51. Wahle E., Keller W. The biochemistry of 3′-end cleavage and polyadenylation of messenger RNA precursors. Annu. Rev. Biochem. 61:1992;419-440.
52. Wang J., Sun L., Myeroff L., Wang X., Gentry L. E., Yang J., Liang J., Zborowska E., Markowitz S., Willson J. K. Demonstration that mutation of the type II transforming growth factor β receptor inactivates its tumor suppressor activity in replication error-positive colon carcinoma cells. J. Biol. Chem. 270:1995;22044-22049.
53. Yingling J. M., Wang X.-F., Bassing C.H. Signaling by the transforming growth factor-β receptors. Biochim. Biophys. Acta. 1242:1995;115-136.
54. Yingling J. M., Das P., Savage C., Zhang M., Padgett R. W., Wang X.-F. Mammalian dwarfins are phosphorylated in response to transforming growth factor β and are implicated in control of cell growth. Proc. Natl. Acad. Sci. USA. 93:1996;8940-8944.
55. Zhang Y., Feng X.-H., Wu R.-Y., Derynck R. Receptor-associated Mad homologues synergize as effectors of the TGF-β response. Nature. 383:1996;168-172.